Probiotics offer promising potential in managing urinary tract infections (UTIs) by restoring and maintaining a healthy balance of bacteria in the urinary tract. Specifically, certain strains like Lactobacillus and Bifidobacterium have shown efficacy in inhibiting the growth of harmful bacteria like E. coli, which commonly causes UTIs. These beneficial bacteria colonize the gut and subsequently migrate to the urinary tract, where they compete with pathogens for nutrients and binding sites, thus reducing the risk of infection. Additionally, prebiotics, such as fructooligosaccharides, serve as nourishment for these probiotics, enhancing their survival and activity. By bolstering the body's natural defenses and promoting a robust microbial ecosystem, probiotics and prebiotics present a promising avenue for UTI prevention and management. However, further research is needed to elucidate optimal strains, dosages, and formulations for maximal efficacy.
Title : Results from a cross-sectional observational study examining irritable bowel syndrome patients six months after finishing their participation in the ViIBS trial
Jacek Piatek, Calisia University, Poland
Title : Gut microbiome as a driver of healthy ageing
Thi Thu Hao Van, RMIT University, Australia
Title : Treating irritable bowel syndrome patients with a balanced multi-strain synbiotic–results from a multi-center, randomized, double-blind, placebo-controlled clinical trial (the ViIBS trial)
Henning Sommermeyer, Calisia University, Poland
Title : Molecular mechanisms underlying the anti-atherogenic actions of probiotics
Dipak P Ramji, Cardiff University, United Kingdom
Title : Global regulatory trends on the use of probiotics and prebiotics in foods and food supplements
David Pineda Ereno, DPE International Consulting, Belgium
Title : Biochemical profile and nutripotential glimpses of Terminalia arjuna bark extract
Suriyavathana Muthukrishnan, Periyar University, India